Wound Management Technologies engages Miller Tabak to execute its plans for 2010

NewsGuard 100/100 Score

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today that it has engaged National Investment Banking firm Miller Tabak & Co., LLC, a twenty-eight year old institutional trading firm as part of its strategy in accelerating the search for potential partners that will help grow revenues, which are necessary to execute Wound Managements plans for 2010. According to Deborah Jenkins Hutchinson, Wound Management President, "We believe that partnering with Miller Tabak will be a key relationship to help us identify the partners that will benefit WMT the most and will help us to reach our strategic goals this year more quickly." The agreement is performance based.

Since 1982, Miller Tabak has gained tremendous experience and expertise in stocks and options transactions as well as creating a vast network using electronic markets and information sources. Today, MT has the most advanced technology systems available helping to create proprietary expert strategies, providing clients with split second accuracy and opportune reactions to market conditions. Offices in New York, Boston, and San Diego provide them with a country-wide footprint from which to operate.

SOURCE Wound Management Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care